Review Article

Lipoproteins as Markers for Monitoring Cancer Progression

Table 3

List of the risk of bias in the studies.

DomainElementsBenn et al. [19]Bhat et al. [17]Brantley et al. [33]Crespo et al. [30]Diakowska et al. [14]Hu et al. [15]Jamnagerwalla et al. [12]Kumar et al. [21]Laisupasin et al. [22]Lofterød et al. [31]Llanos et al. [18]Ma et al. [29]Mosapasour et al. [34]Nowak et al. [20]Raza et al. [24]Rodrigues dos Santos et al. [25, 26]Saito et al. [28]Wan et al. [23]Xie et al. [27]Yang et al. [13]Yuan et al. [32]

Study questionClearly focused and appropriate questionAAAAAAAAAAAAAAAAAAAAA
Study populationDescription of study populationAAAAAAAAAAAAAAAAAAAAA
Sample size justificationAAAAAAAAAAANRNRAAAAAAAA
Comparability of subjectsSpecific inclusion/exclusion criteriaAAAAAAAAAAAAAAAAAAAAA
Criteria applied equally to all groupsAAAAAAAAAAAAAAAAAAAAA
Comparability of groups at baseline with regard to disease status and prognostic factorsAaAAaAAAaaaaAaaAAAaAa
Study groups comparable to nonparticipants with regard to confounding factorsaAaaAaaaAaaaIaIaaNRaNRa
Use of concurrent controlsAAaaAaaaAaaaAaAaaAaIa
Comparability of follow-up among groupsAaaAaAAaaaaaaaaAAaaaa
Exposure or interventionClear definition of exposureAAAAAAAAAAAAAAAAAAAAA
Measurement method standard, valid, and reliableAAAAAAAAAAAAAAAAAAAAA
Exposure measured equally in all study groupsAAAAAAAAAAAAAAAAAAAAA
Outcome measurementPrimary/secondary outcomes clearly definedAAAAAAAAAAAAAAAAAAAAA
Outcomes assessed blind to exposure or intervention statusaaaaaaAaaaaaaaaaaaaaA
Method of outcome assessment standard, valid, and reliableAAAAAAAAAAAAAAAAAAAAA
Length of follow-up adequate for questionAaAAaAAaaaaaaaaAAaaaa
Statistical analysisStatistical tests appropriateAAAAAAAAAAAAIAAAAAAAA
Multiple comparisons taken into considerationANRAAIAAANRANRNRNRANRAAAANRA
Modelling and multivariate techniques appropriateANRAAAAAANRANRNRNRANRAAAANRA
Power calculation providedANRNRNRAAAANRAANRNRANRNRNRNRNRNRNR
Assessment of confounding variablesANRAAAAAANRAaNRNRANRAANRNRNRA
Dose–response assessment, if appropriateaaaaaaaaaaaaaaaaaaaaa
ResultsMeasure of effect for outcomes and appropriate measure of precisionAAAAAAAAAAAAAAAAAAAAA
Adequacy of follow-up for each study groupAaAAaAAaaaaaaaaAAaaaa
DiscussionConclusions supported by results with biases and limitations taken into considerationAaANRAAAAAAANRIAIAAAAII
Funding or sponsorshipType and sources of support for studyANRAANRAANRAAAAAANRAANRAAA

A: adequate; I: inadequate; NR: not reported; a: not applicable to the study design.